Clinical trial · Interventional
Evaluation of the Humoral and Tumoral Molecular Alteration Profile of Brain Metastases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to determine in brain metastases and according to feasibility in liquid biopsies: * Molecular alterations including in particular mutations, amplifications, Copy number gene variants and fusion transcripts identified by high-throughput sequencing; * The rate of variation either in gain or in loss of expression of the different messenger Ribonucleic Acids by analysis of the transcriptome; * Epigenetic alterations by methylation of deoxyribonucleic acid clusters by methylome chips.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biological samples (blood test and lumbar puncture) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- brain metastases from solid cancer
- description
- Excision of the cerebral metastasis
- interventionNames
- Procedure: biological samples (blood test and lumbar puncture)
Primary outcomes (1)
- measure
- molecular alteration profile of liquid biopsies
- timeFrame
- 1 day
- description
- Compare the molecular alteration profile of liquid biopsies (blood and CSF) to that of brain metastases. Will be determined in brain metastases and according to feasibility in liquid biopsies (blood and CSF): * Molecular alterations including in particular mutations, amplifications, Copy number gene variants and fusion transcripts identified by high-throughput sequencing ; * The rate of variation either in gain or in loss of expression of the different messenger Ribonucleic Acids by analysis of the transcriptome ; * Epigenetic alterations by methylation of deoxyribonucleic acid clusters by methylome chips.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient aged 18 or over; * Patient with cerebral metastases from a solid cancer, at least one of which is accessible to surgical excision (contrast enhancement of at least 1 cm); * Patient able to understand the information related to the study and to read the information leaflet; * Patient having signed a written informed consent to participate in the study. Exclusion Criteria: * Patient with a medical contraindication to surgery and anesthesia; * Patient whose anatomical location of the cerebral metastasis contraindicates wide resection; * Patient with a contraindication to performing a lumbar puncture; * Pregnant, parturient or breastfeeding women; * Patient participating in another clinical trial, or in a period of exclusion from another clinical trial; * Patient under guardianship or curatorship, or under a regime of deprivation of liberty; * Patient not benefiting from a social security scheme.
References
Publications (0)
Data not yet available